Create a free Cannabis Equipment News account to continue

MedPharm Scores Funding for Alzheimer's CBD Treatment Research

Anticipated start date of the project is October 1, 2022.

I Stock 1250579263
iStock

MedPharm Research said its proposal, which was submitted to the FY23 Cannabis Research Opportunity at the Colorado State University Institute of Cannabis Research (ICR), titled “Isolation and Pharmacological Evaluation of Phytocannabinoids for Alzheimer’s Disease,” has been selected for funding.

“The study results will allow MedPharm to further develop innovative, bioavailable, and bioequivalent dosage forms. These are important elements in support of Investigational New Drugs (INDs) and New Drug Applications (NDAs) for future FDA-approved products,” said Scott Karolchyk, MS, RPh, Director of Formulation and Development.

The phytocannabinoid cannabidiol (CBD) has neuroprotective, antioxidant and anti-inflammatory properties. Other studies have shown that CBD has been shown to be effective in vivo, making the phytocannabinoid an interesting candidate for novel therapeutic interventions in Alzheimer’s therapy, especially because there are no psychoactive or cognition-impairing properties, thus adding to the significance of the MedPharm study.

“It’s by pursuing this one-of-a-kind study in an area where research is really needed that sets MedPharm apart from other cannabis research and development companies,” Albert Gutierrez, President of MedPharm, says. “Alzheimer’s is a terrible brain disease. Any way we can provide therapies to help treat it, such as doing a pharmacological evaluation to find out what a certain compound can do, we know helps us close in on a better understanding of Alzheimer’s, and perhaps a pathway to greater and more helpful cannabis-based therapies down the road.”

Anticipated start date of the project is October 1, 2022.

More in Manufacturing